Catalog No.
KDE03401
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative competitive enzyme immunoassay technique. Abatacept has been pre-coated onto a microplate. Standards or samples are premixed with Biotin labeled antibody specific for Abatacept and then pipetted into the wells. Abatacept in the sample competitively binds to Biotin labeled antibody specific for Abatacept with pre-coated Abatacept. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Abatacept bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Abatacept concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
125 - 8,000 ng/mL
Sensitivity
59.47 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
4119.3
|
937.7
|
189.8
|
4203.2
|
908.9
|
141.0
|
|
Standard deviation
|
509.9
|
84.8
|
21.7
|
682.4
|
90.7
|
27.0
|
|
CV (%)
|
12.4
|
9.0
|
11.4
|
16.2
|
10.0
|
19.1
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
CAS: 332348-12-6
Note
For Research Use Only.
Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis., PMID:40091354
Update in GVHD Prophylaxis: Novel Pharmacologic and Graft Manipulation Strategies., PMID:40123545
Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment., PMID:40142915
Successful treatment of rheumatoid arthritis complicated by anti-Jo-1 antibody-positive myopathy with abatacept: A case report., PMID:40159152
Verification of unmet medical needs in patients with juvenile idiopathic arthritis in Japan., PMID:40160024
Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis., PMID:40178703
Emerging therapeutics in the management of food allergy., PMID:40189990
Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors., PMID:40199607
Impact of csDMARDs vs. b/tsDMARDs on the Prognosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Multicenter, Retrospective Study., PMID:40218150
Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database., PMID:40232336
Long-Term Outcomes of Belatacept Versus Tacrolimus Following T-Cell Depleting Induction in Adult Kidney Transplantation., PMID:40232892
Macrophage requirements for abatacept response in rheumatoid arthritis., PMID:40242906
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction., PMID:40246381
Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents., PMID:40249052
Recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease: A scoping review., PMID:40256995
Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritis., PMID:40259340
Macrophage-Tased Dual-Phase T Cell Immunomodulation to Combat Transplant Rejection., PMID:40264278
Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD)., PMID:40272902
Real-World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020-2022., PMID:40276902
Short Form-36 psychometric properties in idiopathic inflammatory myopathies: reliability, validity, and responsiveness., PMID:40279268
Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study., PMID:40280051
Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial., PMID:40281208
Toxoplasma Gondii Replication During Belatacept Treatment in Kidney Transplantation: A Case Report and a Review of the Literature., PMID:40282351
SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial., PMID:40297751
Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation., PMID:40301664
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland., PMID:40334913
Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis., PMID:40335724
Cost evaluation in head and neck cancer clinical trials: implications for high-value care., PMID:40339439
Abatacept-induced lupus erythematosus tumidus: A case report and literature review., PMID:40342196
The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid-Induced Fibrosis Mice., PMID:40344312
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis., PMID:40347194
Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes., PMID:40374481
Humoral immunogenicity after vaccination with the fourth dose of COVID-19 in patients with immunomediated inflammatory diseases., PMID:40378626
Disseminated cat-scratch disease during abatacept therapy for rheumatoid arthritis in an older patient: A case report and review of the literature., PMID:40379021
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A report from the CIBMTR., PMID:40398621
β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 Diabetes., PMID:40424079
New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review., PMID:40430462
Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review., PMID:40431608
FDA Approval Summary: Abatacept for prophylaxis of acute graft versus host disease., PMID:40435096
Multi-omics analysis of Helicobacter pylori-associated gastric cancer identifies hub genes as a novel therapeutic biomarker., PMID:40445003
Switching to IL-6 inhibitors or abatacept in elderly patients with rheumatoid arthritis achieving low disease activity with jak inhibitors: a pilot study., PMID:40455033
Autoantibodies as prognostic markers in rheumatoid arthritis., PMID:40458132
Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders., PMID:40465294
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650
Allogeneic Transplantation for Older Adults., PMID:40488822
Optimal GVHD Prophylaxis., PMID:40488825
Abatacept and multiple therapeutic bronchoscopies as salvage therapy for refractory tracheobronchial inflammation and stenosis in GPA., PMID:40506105
A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe, granulomatosis with polyangiitis., PMID:40506793
For research use only. Not for human or drug use.
